When Fraud Reaches the Exam Room

The federal case against Anchorage rheumatologist Claribel Tan should not be read as a routine fraud prosecution with unusually vivid facts. In a March 17 sentencing release from the U.S. Attorney’s Office for the District of Alaska, the Department of Justice said the scheme involved more than $12.5 million in health care fraud, more than $4.2 million in tax loss, and conduct that stretched across 15 years. What makes the case editorially important is not only the money. It is the allegation that the fraud was built into treatment itself.

According to the same sentencing release, patients were allegedly underdosed, given free samples or different drugs than prescribed, injected with expired medication, and billed as though proper doses had been administered. Federal prosecutors said the clinic billed insurers for 4,829 units of medication while purchasing only 369 units. That is not the familiar image of fraud as paperwork manipulation detached from patient care. It is a case in which the financial deception and the clinical deception appear to have been inseparable.

Why this case is bigger than one physician

Healthcare fraud is often discussed as though it begins and ends with false claims. That framing is too narrow. Some fraud cases are really documentation cases. Some are coding cases. Some are referral cases. This one points to a more serious category: fraud that changes what the patient actually receives. When that happens, the violation is not just against a payer or the Treasury. It is against the patient’s expectation that treatment decisions are being made for medical reasons rather than inventory convenience or financial gain.

That distinction matters because the American healthcare system still tends to separate compliance risk from patient-safety risk. One team worries about billing integrity. Another worries about clinical quality. Another worries about pharmacy controls. In a case like this, those silos become a liability. If the allegations described in the Justice Department’s release are accurate, the same conduct distorted billing, tax reporting, medication handling, and clinical care at once. Oversight models that treat those domains as separate are poorly matched to how real misconduct can unfold.

The physician-administered drug problem remains vulnerable

The setting matters here. Physician-administered drugs have long posed a difficult oversight challenge because they sit inside the so-called buy-and-bill environment, where acquisition, storage, administration, documentation, and reimbursement all intersect in a single workflow. On its drug spending oversight page, the HHS Office of Inspector General notes that Medicare Part B is largely a program for physician-administered drugs and says the office has spent decades highlighting reimbursement vulnerabilities and program-compliance risks in this area. When high-cost injectables move through opaque office-based systems, the line between operational sloppiness and intentional abuse can narrow quickly.

The allegations involving free samples are especially revealing. In its physician compliance education, HHS OIG states that drug and biologic samples may legally be given to patients for free, but that it is illegal to sell those samples, and it specifically warns that physicians need reliable systems to keep samples separate from commercial stock because the government has prosecuted physicians for billing Medicare for free samples. That warning appears in OIG’s guidance on physician relationships with vendors. In other words, the federal government has been explicit for years that sample management is not a minor housekeeping issue. It is a known compliance and enforcement risk.

That is why this case should unsettle health systems and physician groups beyond Alaska. The troubling feature is not simply that one practice allegedly broke rules. It is that the alleged methods were structurally possible inside a routine specialty workflow involving expensive injectable therapies, inventory handling, and insurer reimbursement. Any organization that administers drugs in office settings should see the case as a test of whether inventory records, expiration controls, dose documentation, and claims submission are truly reconciled in near real time.

The numbers still matter

None of this minimizes the financial dimension. It sharpens it. In its fiscal year 2025 False Claims Act announcement, the Justice Department said more than $5.7 billion of the year’s $6.8 billion in False Claims Act recoveries involved the health care industry, and it made a point of noting that these cases often protect patients from medically unnecessary or potentially harmful conduct. That language is important because it reflects a broader enforcement reality. Federal fraud work is no longer framed only as a taxpayer-protection effort. It is increasingly presented as a patient-protection effort too.

The same dual reality shows up in federal payment data. In its fiscal year 2025 improper payments fact sheet, CMS reported $28.83 billion in Medicare fee-for-service improper payments, $23.67 billion in Medicare Advantage improper payments, and $37.39 billion in Medicaid improper payments, while noting that many are driven by insufficient documentation rather than fraud. That distinction is important. Most documentation failures are not criminal. But the scale of those weaknesses should still worry the industry. A payment environment that already struggles to verify support for claims will always be more exposed to the smaller subset of cases where documentation problems are deliberate and clinically consequential.

What health care organizations should take from this

The usual response to a fraud case is to ask whether a compliance policy existed on paper. That is the wrong question. Most organizations have policies. The better question is whether the controls match the workflow. In office-based specialty practices, that means reconciling purchased drug volume to administered dose volume, keeping sample stock physically and digitally separate from billable inventory, monitoring expiration dates and storage conditions, and flagging any material mismatch between claims patterns and acquisition patterns. A clinic should not be able to bill for thousands of units while buying only a fraction of that amount without triggering internal alarms long before prosecutors arrive.

There is a cultural lesson as well. Healthcare sometimes treats fraud as an external legal hazard instead of an internal operational signal. That mindset delays intervention. When a physician or clinic begins showing implausible utilization, inconsistent inventory, or unusual billing against high-cost drugs, the issue should not be routed only to finance or legal. It should be treated as a potential quality-of-care event. Once the possibility exists that patients may be receiving the wrong dose, the wrong product, or expired medication, compliance becomes a clinical matter.

The Alaska case also underscores that accountability does not end with conviction. The sentencing release says prosecutors seized roughly $10.4 million in fraud proceeds, the defendants paid $6.3 million toward future restitution, paid an additional $1.8 million to settle civil claims, and that Dr. Tan surrendered her medical license. Those outcomes are significant, but they are still retrospective. The larger challenge is building systems that surface this kind of conduct before it lasts for years and before patients become part of the loss calculation.

Where the industry should stop looking away

The most useful way to read this case is not as an outlier, and not as proof that every documentation discrepancy hides malice. It is a warning about what happens when healthcare keeps treating billing integrity, medication management, and patient protection as separate disciplines. Fraud becomes most dangerous when it can wear the mask of routine care. In that environment, the absence of strong controls is not merely an accounting weakness. It is an invitation to clinical betrayal.